MMAF Hydrochloride is primarily used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It functions as a potent cytotoxic agent that is linked to monoclonal antibodies, which are designed to specifically recognize and bind to cancer cells. Once the ADC binds to the target cell, it is internalized, and MMAF is released, leading to cell death by inhibiting microtubule polymerization and disrupting cell division. This targeted approach minimizes damage to healthy cells, reducing side effects compared to traditional chemotherapy. MMAF Hydrochloride is particularly valuable in treating cancers that are difficult to address with conventional therapies, such as certain types of lymphomas and solid tumors. Its application is a key area of research in advancing personalized medicine and improving treatment outcomes for cancer patients.